Rare diseases
Investigational molecules
Locations
A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
PolandStudy of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy
PolandStudy of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease
PolandStudy of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma
PolandSafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
PolandStudy of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients
PolandEffect of Ferric Carboxymaltose, Ferrous Sulfate, and Sodium Chloride vs Placebo on Physical Performance in Frail Elderly with Iron Deficiency and Cardiovascular Disease
PolandRandomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration
PolandPhase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients
PolandEvaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A
PolandA Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors
PolandStudy of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma
PolandTell us about your condition – we search every trial in Europe and connect you with the right site.
